APO Research
Talk to an analyst

APO RESEARCH · REPORT

Expectorant Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Expectorant Drug Industry Research Report 2026

22 December 2025150 pages

Choose your research edition.

Industry ResearchExpectorant Drug Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Expectorant Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Expectorant Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Expectorant Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Expectorant Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Expectorant Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Expectorant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Expectorant Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Expectorant Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Expectorant Drug include Sanofi SA, lohnson and Johnson, Merck KGaA, Pfizer Inc., GlaxoSmithKline plc., Astrazeneca Plc., Vernalis plc, Tris Pharma Inc. and The Himalaya Drug Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Expectorant Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Expectorant Drug Market by Company

Sanofi SA

lohnson and Johnson

Merck KGaA

Pfizer Inc.

GlaxoSmithKline plc.

Astrazeneca Plc.

Vernalis plc

Tris Pharma Inc.

The Himalaya Drug Company

Taro Pharmaceutical Industries Ltd.

Reckitt Benckiser Group plc

Proctor and Gamble Co

Perrigo Company plc

Novartis International AG

Mayne Pharma Inc.

Glenmark Pharmaceuticals Limited

Dabur India Ltd

Cipla Limited

Aytu BioScience Inc.

Aurobindo Pharma Ltd

Amneal Pharmaceuticals LLC

Acella Pharmaceuticals LLC

Abbott Laboratories

Expectorant Drug Segment by Type

Inhalants

Oral Liquid

Oral Solid

Expectorant Drug Segment by Application

Hospital

Clinic

Other

Expectorant Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Expectorant Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Expectorant Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Expectorant Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Expectorant Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Expectorant Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Expectorant Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Expectorant Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Expectorant Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Expectorant Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Expectorant Drug Revenue of Manufacturers (2021-2026) Table 9. Global Expectorant Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Expectorant Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Expectorant Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Expectorant Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Expectorant Drug, Product Type & Application Table 14. Global Expectorant Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Expectorant Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi SA Company Information Table 19. Sanofi SA Business Overview Table 20. Sanofi SA Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Sanofi SA Expectorant Drug Product Portfolio Table 22. Sanofi SA Recent Developments Table 23. lohnson and Johnson Company Information Table 24. lohnson and Johnson Business Overview Table 25. lohnson and Johnson Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. lohnson and Johnson Expectorant Drug Product Portfolio Table 27. lohnson and Johnson Recent Developments Table 28. Merck KGaA Company Information Table 29. Merck KGaA Business Overview Table 30. Merck KGaA Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Merck KGaA Expectorant Drug Product Portfolio Table 32. Merck KGaA Recent Developments Table 33. Pfizer Inc. Company Information Table 34. Pfizer Inc. Business Overview Table 35. Pfizer Inc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Pfizer Inc. Expectorant Drug Product Portfolio Table 37. Pfizer Inc. Recent Developments Table 38. GlaxoSmithKline plc. Company Information Table 39. GlaxoSmithKline plc. Business Overview Table 40. GlaxoSmithKline plc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline plc. Expectorant Drug Product Portfolio Table 42. GlaxoSmithKline plc. Recent Developments Table 43. Astrazeneca Plc. Company Information Table 44. Astrazeneca Plc. Business Overview Table 45. Astrazeneca Plc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Astrazeneca Plc. Expectorant Drug Product Portfolio Table 47. Astrazeneca Plc. Recent Developments Table 48. Vernalis plc Company Information Table 49. Vernalis plc Business Overview Table 50. Vernalis plc Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Vernalis plc Expectorant Drug Product Portfolio Table 52. Vernalis plc Recent Developments Table 53. Tris Pharma Inc. Company Information Table 54. Tris Pharma Inc. Business Overview Table 55. Tris Pharma Inc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Tris Pharma Inc. Expectorant Drug Product Portfolio Table 57. Tris Pharma Inc. Recent Developments Table 58. The Himalaya Drug Company Company Information Table 59. The Himalaya Drug Company Business Overview Table 60. The Himalaya Drug Company Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. The Himalaya Drug Company Expectorant Drug Product Portfolio Table 62. The Himalaya Drug Company Recent Developments Table 63. Taro Pharmaceutical Industries Ltd. Company Information Table 64. Taro Pharmaceutical Industries Ltd. Business Overview Table 65. Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Taro Pharmaceutical Industries Ltd. Expectorant Drug Product Portfolio Table 67. Taro Pharmaceutical Industries Ltd. Recent Developments Table 68. Reckitt Benckiser Group plc Company Information Table 69. Reckitt Benckiser Group plc Business Overview Table 70. Reckitt Benckiser Group plc Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Reckitt Benckiser Group plc Expectorant Drug Product Portfolio Table 72. Reckitt Benckiser Group plc Recent Developments Table 73. Proctor and Gamble Co Company Information Table 74. Proctor and Gamble Co Business Overview Table 75. Proctor and Gamble Co Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Proctor and Gamble Co Expectorant Drug Product Portfolio Table 77. Proctor and Gamble Co Recent Developments Table 78. Perrigo Company plc Company Information Table 79. Perrigo Company plc Business Overview Table 80. Perrigo Company plc Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Perrigo Company plc Expectorant Drug Product Portfolio Table 82. Perrigo Company plc Recent Developments Table 83. Novartis International AG Company Information Table 84. Novartis International AG Business Overview Table 85. Novartis International AG Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Novartis International AG Expectorant Drug Product Portfolio Table 87. Novartis International AG Recent Developments Table 88. Mayne Pharma Inc. Company Information Table 89. Mayne Pharma Inc. Business Overview Table 90. Mayne Pharma Inc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Mayne Pharma Inc. Expectorant Drug Product Portfolio Table 92. Mayne Pharma Inc. Recent Developments Table 93. Glenmark Pharmaceuticals Limited Company Information Table 94. Glenmark Pharmaceuticals Limited Business Overview Table 95. Glenmark Pharmaceuticals Limited Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Glenmark Pharmaceuticals Limited Expectorant Drug Product Portfolio Table 97. Glenmark Pharmaceuticals Limited Recent Developments Table 98. Dabur India Ltd Company Information Table 99. Dabur India Ltd Business Overview Table 100. Dabur India Ltd Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Dabur India Ltd Expectorant Drug Product Portfolio Table 102. Dabur India Ltd Recent Developments Table 103. Cipla Limited Company Information Table 104. Cipla Limited Business Overview Table 105. Cipla Limited Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Cipla Limited Expectorant Drug Product Portfolio Table 107. Cipla Limited Recent Developments Table 108. Aytu BioScience Inc. Company Information Table 109. Aytu BioScience Inc. Business Overview Table 110. Aytu BioScience Inc. Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Aytu BioScience Inc. Expectorant Drug Product Portfolio Table 112. Aytu BioScience Inc. Recent Developments Table 113. Aurobindo Pharma Ltd Company Information Table 114. Aurobindo Pharma Ltd Business Overview Table 115. Aurobindo Pharma Ltd Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Aurobindo Pharma Ltd Expectorant Drug Product Portfolio Table 117. Aurobindo Pharma Ltd Recent Developments Table 118. Amneal Pharmaceuticals LLC Company Information Table 119. Amneal Pharmaceuticals LLC Business Overview Table 120. Amneal Pharmaceuticals LLC Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Amneal Pharmaceuticals LLC Expectorant Drug Product Portfolio Table 122. Amneal Pharmaceuticals LLC Recent Developments Table 123. Acella Pharmaceuticals LLC Company Information Table 124. Acella Pharmaceuticals LLC Business Overview Table 125. Acella Pharmaceuticals LLC Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Acella Pharmaceuticals LLC Expectorant Drug Product Portfolio Table 127. Acella Pharmaceuticals LLC Recent Developments Table 128. Abbott Laboratories Company Information Table 129. Abbott Laboratories Business Overview Table 130. Abbott Laboratories Expectorant Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Abbott Laboratories Expectorant Drug Product Portfolio Table 132. Abbott Laboratories Recent Developments Table 133. Global Expectorant Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 134. Global Expectorant Drug Sales by Region (2021-2026) & (k units) Table 135. Global Expectorant Drug Sales Market Share by Region (2021-2026) Table 136. Global Expectorant Drug Sales by Region (2027-2032) & (k units) Table 137. Global Expectorant Drug Sales Market Share by Region (2027-2032) Table 138. Global Expectorant Drug Revenue by Region (2021-2026) & (US$ Million) Table 139. Global Expectorant Drug Revenue Market Share by Region (2021-2026) Table 140. Global Expectorant Drug Revenue by Region (2027-2032) & (US$ Million) Table 141. Global Expectorant Drug Revenue Market Share by Region (2027-2032) Table 142. North America Expectorant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. North America Expectorant Drug Sales by Country (2021-2026) & (k units) Table 144. North America Expectorant Drug Sales by Country (2027-2032) & (k units) Table 145. North America Expectorant Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. North America Expectorant Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. Europe Expectorant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Europe Expectorant Drug Sales by Country (2021-2026) & (k units) Table 149. Europe Expectorant Drug Sales by Country (2027-2032) & (k units) Table 150. Europe Expectorant Drug Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Expectorant Drug Revenue by Country (2027-2032) & (US$ Million) Table 152. Asia Pacific Expectorant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Asia Pacific Expectorant Drug Sales by Country (2021-2026) & (k units) Table 154. Asia Pacific Expectorant Drug Sales by Country (2027-2032) & (k units) Table 155. Asia Pacific Expectorant Drug Revenue by Country (2021-2026) & (US$ Million) Table 156. Asia Pacific Expectorant Drug Revenue by Country (2027-2032) & (US$ Million) Table 157. South America Expectorant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. South America Expectorant Drug Sales by Country (2021-2026) & (k units) Table 159. South America Expectorant Drug Sales by Country (2027-2032) & (k units) Table 160. South America Expectorant Drug Revenue by Country (2021-2026) & (US$ Million) Table 161. South America Expectorant Drug Revenue by Country (2027-2032) & (US$ Million) Table 162. Middle East and Africa Expectorant Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Middle East and Africa Expectorant Drug Sales by Country (2021-2026) & (k units) Table 164. Middle East and Africa Expectorant Drug Sales by Country (2027-2032) & (k units) Table 165. Middle East and Africa Expectorant Drug Revenue by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Expectorant Drug Revenue by Country (2027-2032) & (US$ Million) Table 167. Global Expectorant Drug Sales by Type (2021-2026) & (k units) Table 168. Global Expectorant Drug Sales by Type (2027-2032) & (k units) Table 169. Global Expectorant Drug Sales Market Share by Type (2021-2026) Table 170. Global Expectorant Drug Sales Market Share by Type (2027-2032) Table 171. Global Expectorant Drug Revenue by Type (2021-2026) & (US$ Million) Table 172. Global Expectorant Drug Revenue by Type (2027-2032) & (US$ Million) Table 173. Global Expectorant Drug Revenue Market Share by Type (2021-2026) Table 174. Global Expectorant Drug Revenue Market Share by Type (2027-2032) Table 175. Global Expectorant Drug Price by Type (2021-2026) & (US$/unit) Table 176. Global Expectorant Drug Price by Type (2027-2032) & (US$/unit) Table 177. Global Expectorant Drug Sales by Application (2021-2026) & (k units) Table 178. Global Expectorant Drug Sales by Application (2027-2032) & (k units) Table 179. Global Expectorant Drug Sales Market Share by Application (2021-2026) Table 180. Global Expectorant Drug Sales Market Share by Application (2027-2032) Table 181. Global Expectorant Drug Revenue by Application (2021-2026) & (US$ Million) Table 182. Global Expectorant Drug Revenue by Application (2027-2032) & (US$ Million) Table 183. Global Expectorant Drug Revenue Market Share by Application (2021-2026) Table 184. Global Expectorant Drug Revenue Market Share by Application (2027-2032) Table 185. Global Expectorant Drug Price by Application (2021-2026) & (US$/unit) Table 186. Global Expectorant Drug Price by Application (2027-2032) & (US$/unit) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Expectorant Drug Distributors List Table 190. Expectorant Drug Customers List Table 191. Expectorant Drug Industry Trends Table 192. Expectorant Drug Industry Drivers Table 193. Expectorant Drug Industry Restraints Table 194. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Expectorant Drug Product Image Figure 5. Global Expectorant Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Expectorant Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Expectorant Drug Sales (2021-2032) & (k units) Figure 8. Global Expectorant Drug Average Price (US$/unit) & (2021-2032) Figure 9. Inhalants Product Image Figure 10. Oral Liquid Product Image Figure 11. Oral Solid Product Image Figure 12. Hospital Product Image Figure 13. Clinic Product Image Figure 14. Other Product Image Figure 15. Global Expectorant Drug Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Expectorant Drug, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Expectorant Drug Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Expectorant Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Expectorant Drug Sales by Region in 2025 Figure 21. Global Expectorant Drug Revenue by Region in 2025 Figure 22. North America Expectorant Drug Market Size by Country in 2025 Figure 23. North America Expectorant Drug Sales Market Share by Country (2021-2032) Figure 24. North America Expectorant Drug Revenue Market Share by Country (2021-2032) Figure 25. United States Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Expectorant Drug Market Size by Country in 2025 Figure 29. Europe Expectorant Drug Sales Market Share by Country (2021-2032) Figure 30. Europe Expectorant Drug Revenue Market Share by Country (2021-2032) Figure 31. Germany Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Expectorant Drug Market Size by Country in 2025 Figure 42. Asia Pacific Expectorant Drug Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Expectorant Drug Revenue Market Share by Country (2021-2032) Figure 44. China Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Expectorant Drug Market Size by Country in 2025 Figure 53. South America Expectorant Drug Sales Market Share by Country (2021-2032) Figure 54. South America Expectorant Drug Revenue Market Share by Country (2021-2032) Figure 55. Brazil Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Expectorant Drug Market Size by Country in 2025 Figure 59. Middle East and Africa Expectorant Drug Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Expectorant Drug Revenue Market Share by Country (2021-2032) Figure 61. Egypt Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Expectorant Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Expectorant Drug Sales Market Share by Type (2021-2032) Figure 67. Global Expectorant Drug Revenue Market Share by Type (2021-2032) Figure 68. Global Expectorant Drug Price (US$/unit) by Type (2021-2032) Figure 69. Global Expectorant Drug Sales Market Share by Application (2021-2032) Figure 70. Global Expectorant Drug Revenue Market Share by Application (2021-2032) Figure 71. Global Expectorant Drug Price (US$/unit) by Application (2021-2032) Figure 72. Expectorant Drug Value Chain Figure 73. Expectorant Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Expectorant Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Inhalants
  • Oral Liquid
  • Oral Solid
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Sanofi SA
  • lohnson and Johnson
  • Merck KGaA
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Astrazeneca Plc.
  • Vernalis plc
  • Tris Pharma Inc.
  • The Himalaya Drug Company
  • Taro Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Proctor and Gamble Co
  • Perrigo Company plc
  • Novartis International AG
  • Mayne Pharma Inc.
  • Glenmark Pharmaceuticals Limited
  • Dabur India Ltd
  • Cipla Limited
  • Aytu BioScience Inc.
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals LLC
  • Acella Pharmaceuticals LLC
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Expectorant Drug Market Size (2021-2032)
  4. 2.2.2 Global Expectorant Drug Sales (2021-2032)
  5. 2.2.3 Global Expectorant Drug Market Average Price (2021-2032)
  6. 2.3 Expectorant Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Inhalants
  9. 2.3.3 Oral Liquid
  10. 2.3.4 Oral Solid
  11. 2.4 Expectorant Drug by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Clinic
  15. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Expectorant Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Expectorant Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Expectorant Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Expectorant Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Expectorant Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Expectorant Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Expectorant Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Expectorant Drug, Established Date
  9. 3.9 Global Expectorant Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi SA
  2. 4.1.1 Sanofi SA Company Information
  3. 4.1.2 Sanofi SA Business Overview
  4. 4.1.3 Sanofi SA Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi SA Expectorant Drug Product Portfolio
  6. 4.1.5 Sanofi SA Recent Developments
  7. 4.2 lohnson and Johnson
  8. 4.2.1 lohnson and Johnson Company Information
  9. 4.2.2 lohnson and Johnson Business Overview
  10. 4.2.3 lohnson and Johnson Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 lohnson and Johnson Expectorant Drug Product Portfolio
  12. 4.2.5 lohnson and Johnson Recent Developments
  13. 4.3 Merck KGaA
  14. 4.3.1 Merck KGaA Company Information
  15. 4.3.2 Merck KGaA Business Overview
  16. 4.3.3 Merck KGaA Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck KGaA Expectorant Drug Product Portfolio
  18. 4.3.5 Merck KGaA Recent Developments
  19. 4.4 Pfizer Inc.
  20. 4.4.1 Pfizer Inc. Company Information
  21. 4.4.2 Pfizer Inc. Business Overview
  22. 4.4.3 Pfizer Inc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Inc. Expectorant Drug Product Portfolio
  24. 4.4.5 Pfizer Inc. Recent Developments
  25. 4.5 GlaxoSmithKline plc.
  26. 4.5.1 GlaxoSmithKline plc. Company Information
  27. 4.5.2 GlaxoSmithKline plc. Business Overview
  28. 4.5.3 GlaxoSmithKline plc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GlaxoSmithKline plc. Expectorant Drug Product Portfolio
  30. 4.5.5 GlaxoSmithKline plc. Recent Developments
  31. 4.6 Astrazeneca Plc.
  32. 4.6.1 Astrazeneca Plc. Company Information
  33. 4.6.2 Astrazeneca Plc. Business Overview
  34. 4.6.3 Astrazeneca Plc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Astrazeneca Plc. Expectorant Drug Product Portfolio
  36. 4.6.5 Astrazeneca Plc. Recent Developments
  37. 4.7 Vernalis plc
  38. 4.7.1 Vernalis plc Company Information
  39. 4.7.2 Vernalis plc Business Overview
  40. 4.7.3 Vernalis plc Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Vernalis plc Expectorant Drug Product Portfolio
  42. 4.7.5 Vernalis plc Recent Developments
  43. 4.8 Tris Pharma Inc.
  44. 4.8.1 Tris Pharma Inc. Company Information
  45. 4.8.2 Tris Pharma Inc. Business Overview
  46. 4.8.3 Tris Pharma Inc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Tris Pharma Inc. Expectorant Drug Product Portfolio
  48. 4.8.5 Tris Pharma Inc. Recent Developments
  49. 4.9 The Himalaya Drug Company
  50. 4.9.1 The Himalaya Drug Company Company Information
  51. 4.9.2 The Himalaya Drug Company Business Overview
  52. 4.9.3 The Himalaya Drug Company Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 The Himalaya Drug Company Expectorant Drug Product Portfolio
  54. 4.9.5 The Himalaya Drug Company Recent Developments
  55. 4.10 Taro Pharmaceutical Industries Ltd.
  56. 4.10.1 Taro Pharmaceutical Industries Ltd. Company Information
  57. 4.10.2 Taro Pharmaceutical Industries Ltd. Business Overview
  58. 4.10.3 Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Taro Pharmaceutical Industries Ltd. Expectorant Drug Product Portfolio
  60. 4.10.5 Taro Pharmaceutical Industries Ltd. Recent Developments
  61. 4.11 Reckitt Benckiser Group plc
  62. 4.11.1 Reckitt Benckiser Group plc Company Information
  63. 4.11.2 Reckitt Benckiser Group plc Business Overview
  64. 4.11.3 Reckitt Benckiser Group plc Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Reckitt Benckiser Group plc Expectorant Drug Product Portfolio
  66. 4.11.5 Reckitt Benckiser Group plc Recent Developments
  67. 4.12 Proctor and Gamble Co
  68. 4.12.1 Proctor and Gamble Co Company Information
  69. 4.12.2 Proctor and Gamble Co Business Overview
  70. 4.12.3 Proctor and Gamble Co Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Proctor and Gamble Co Expectorant Drug Product Portfolio
  72. 4.12.5 Proctor and Gamble Co Recent Developments
  73. 4.13 Perrigo Company plc
  74. 4.13.1 Perrigo Company plc Company Information
  75. 4.13.2 Perrigo Company plc Business Overview
  76. 4.13.3 Perrigo Company plc Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Perrigo Company plc Expectorant Drug Product Portfolio
  78. 4.13.5 Perrigo Company plc Recent Developments
  79. 4.14 Novartis International AG
  80. 4.14.1 Novartis International AG Company Information
  81. 4.14.2 Novartis International AG Business Overview
  82. 4.14.3 Novartis International AG Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Novartis International AG Expectorant Drug Product Portfolio
  84. 4.14.5 Novartis International AG Recent Developments
  85. 4.15 Mayne Pharma Inc.
  86. 4.15.1 Mayne Pharma Inc. Company Information
  87. 4.15.2 Mayne Pharma Inc. Business Overview
  88. 4.15.3 Mayne Pharma Inc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Mayne Pharma Inc. Expectorant Drug Product Portfolio
  90. 4.15.5 Mayne Pharma Inc. Recent Developments
  91. 4.16 Glenmark Pharmaceuticals Limited
  92. 4.16.1 Glenmark Pharmaceuticals Limited Company Information
  93. 4.16.2 Glenmark Pharmaceuticals Limited Business Overview
  94. 4.16.3 Glenmark Pharmaceuticals Limited Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Glenmark Pharmaceuticals Limited Expectorant Drug Product Portfolio
  96. 4.16.5 Glenmark Pharmaceuticals Limited Recent Developments
  97. 4.17 Dabur India Ltd
  98. 4.17.1 Dabur India Ltd Company Information
  99. 4.17.2 Dabur India Ltd Business Overview
  100. 4.17.3 Dabur India Ltd Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Dabur India Ltd Expectorant Drug Product Portfolio
  102. 4.17.5 Dabur India Ltd Recent Developments
  103. 4.18 Cipla Limited
  104. 4.18.1 Cipla Limited Company Information
  105. 4.18.2 Cipla Limited Business Overview
  106. 4.18.3 Cipla Limited Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Cipla Limited Expectorant Drug Product Portfolio
  108. 4.18.5 Cipla Limited Recent Developments
  109. 4.19 Aytu BioScience Inc.
  110. 4.19.1 Aytu BioScience Inc. Company Information
  111. 4.19.2 Aytu BioScience Inc. Business Overview
  112. 4.19.3 Aytu BioScience Inc. Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Aytu BioScience Inc. Expectorant Drug Product Portfolio
  114. 4.19.5 Aytu BioScience Inc. Recent Developments
  115. 4.20 Aurobindo Pharma Ltd
  116. 4.20.1 Aurobindo Pharma Ltd Company Information
  117. 4.20.2 Aurobindo Pharma Ltd Business Overview
  118. 4.20.3 Aurobindo Pharma Ltd Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Aurobindo Pharma Ltd Expectorant Drug Product Portfolio
  120. 4.20.5 Aurobindo Pharma Ltd Recent Developments
  121. 4.21 Amneal Pharmaceuticals LLC
  122. 4.21.1 Amneal Pharmaceuticals LLC Company Information
  123. 4.21.2 Amneal Pharmaceuticals LLC Business Overview
  124. 4.21.3 Amneal Pharmaceuticals LLC Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Amneal Pharmaceuticals LLC Expectorant Drug Product Portfolio
  126. 4.21.5 Amneal Pharmaceuticals LLC Recent Developments
  127. 4.22 Acella Pharmaceuticals LLC
  128. 4.22.1 Acella Pharmaceuticals LLC Company Information
  129. 4.22.2 Acella Pharmaceuticals LLC Business Overview
  130. 4.22.3 Acella Pharmaceuticals LLC Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Acella Pharmaceuticals LLC Expectorant Drug Product Portfolio
  132. 4.22.5 Acella Pharmaceuticals LLC Recent Developments
  133. 4.23 Abbott Laboratories
  134. 4.23.1 Abbott Laboratories Company Information
  135. 4.23.2 Abbott Laboratories Business Overview
  136. 4.23.3 Abbott Laboratories Expectorant Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Abbott Laboratories Expectorant Drug Product Portfolio
  138. 4.23.5 Abbott Laboratories Recent Developments
5 Global Expectorant Drug Market Scenario by Region
  1. 5.1 Global Expectorant Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Expectorant Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Expectorant Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Expectorant Drug Sales by Region: 2027-2032
  5. 5.3 Global Expectorant Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Expectorant Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Expectorant Drug Revenue by Region: 2027-2032
  8. 5.4 North America Expectorant Drug Market Facts & Figures by Country
  9. 5.4.1 North America Expectorant Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Expectorant Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Expectorant Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Expectorant Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Expectorant Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Expectorant Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Expectorant Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Expectorant Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Expectorant Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Expectorant Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Expectorant Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Expectorant Drug Market Facts & Figures by Country
  41. 5.7.1 South America Expectorant Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Expectorant Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Expectorant Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Expectorant Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Expectorant Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Expectorant Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Expectorant Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Expectorant Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Expectorant Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Expectorant Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Expectorant Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Expectorant Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Expectorant Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Expectorant Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Expectorant Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Expectorant Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Expectorant Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Expectorant Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Expectorant Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Expectorant Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Expectorant Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Expectorant Drug Value Chain Analysis
  2. 8.1.1 Expectorant Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Expectorant Drug Production Mode & Process
  5. 8.2 Expectorant Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Expectorant Drug Distributors
  8. 8.2.3 Expectorant Drug Customers
9 Global Expectorant Drug Analyzing Market Dynamics
  1. 9.1 Expectorant Drug Industry Trends
  2. 9.2 Expectorant Drug Industry Drivers
  3. 9.3 Expectorant Drug Industry Opportunities and Challenges
  4. 9.4 Expectorant Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst